Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization

Plain-language guide to PMID 8612858 (1996): multicenter randomized controlled trial study of hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin).

Key Facts

PMID: 8612858
Journal: Fertility and sterility
Year: 1996
Study type: Randomized Controlled Trial
Authors: Urbancsek J et al. (2 authors)

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin).

To establish whether time to down-regulation and pregnancy and live birth rates were different when buserelin acetate was started in the midluteal phase or early follicular phase in IVF-ET patients.

Who Took Part

PubMed tags the participants as women only.

Women attending seven infertility clinics.

One hundred twenty-four women with tubal or unexplained infertility with normal menstruation and fertile partners.

How the Study Was Run

The researchers set it up as a randomized, multicenter and parallel-group study.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

Running at several centres spread the hCG (human chorionic gonadotropin) study over different clinics and patient groups.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Prospective, controlled, randomized, parallel-group multicenter clinical study.

Intranasal buserelin acetate started in the midluteal or early follicular phase combined with standard hMG and hCG stimulation after achievement of down-regulation.

What Was Measured

Topics PubMed links to this paper include Buserelin, Chorionic Gonadotropin, Embryo Transfer, Fertilization in Vitro, Follicular Phase, Luteal Phase and Menotropins.

What This Means in Plain Language

The paper is a randomized, multicenter and parallel-group study of hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1996 (Fertility and sterility), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.

Our Notes on the Compounds

hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.

HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.

Buserelin: A GnRH analog (Suprefact) given by nasal spray or injection, used in prostate cancer and fertility treatment.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.